Stock Ratings / Health Care / ADUS / earnings

WGS (58) PRVA (57) AVAH (65) TDOC (56) ⌘ Pro Terminal →

Addus HomeCare Corporation (ADUS) Next Earnings Date & Expected ±5% Move

$124.34 +1.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Addus HomeCare Corporation (ADUS) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $2.32B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+4.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADUS)Realized 20D OHLCV Swing Band: ±5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±5% Swing Band

±$6.22 Expected Swing

MODEL EARNINGS SETUP GAUGE

ADUS Quantitative Pre-Earnings Setup: 69/100

Trailing EPS: $5.14 • YoY Revenue Growth: 23.2%

Model Bullish Setup (69/100)Model Risk Weight (31/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$1.42B	$95.9M	$103.8M	32.5%
FY 2024	2024-12-31	$1.15B	$73.6M	$110.4M	32.5%
FY 2023	2023-12-31	$1.06B	$62.5M	$112.2M	32.5%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating ADUS & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on ADUS
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ADUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +28.33%▲ ASCENDING CHANNEL

2026-10-30O $125.7H $126.6L $124.3C $124.3VOL 300.3K

RES: $141.6SUP: $111.1SMA50: $117.0SMA200: $106.4

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADUS Butterfly Map → + Track ADUS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

17.9%/yr Implied 5Y Growth

vs. +23.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ADUS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADUS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ADUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADUS)

Health Care Rank #101 of 1016 ⚔️ WGS vs ADUS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADUS vs. WGS, PRVA, AVAH, TDOC)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Addus HomeCare Corporation (ADUS) ranks #101 by composite RQD confidence (69/100, grade C+) and #234 by equity capitalization ($2.32B). Within this direct 5-issuer industry benchmark cohort, ADUS leads on earnings valuation at 24.2x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. ADUS currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ADUS ACTIVE Addus HomeCare Corporation	C+	69/100	24.2x	32.5%	9.1%	+1.77%	$2.32B	Benchmark Subject
WGS GeneDx Holdings Corp. (Class A)	D+	58/100	—	69.7%	-4.1%	+9.79%	$2.12B	/wgs-vs-adus →
PRVA Privia Health Group Inc.	D+	57/100	122.6x	—	10.5%	+0.71%	$2.81B	/prva-vs-adus →
AVAH Aveanna Healthcare Holdings Inc.	C	65/100	—	33.3%	15.7%	+1.53%	$2.89B	/avah-vs-adus →
TDOC Teladoc Health Inc.	D+	56/100	—	—	-17.0%	+26.89%	$1.59B	/tdoc-vs-adus →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001468328

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Addus HomeCare Corporation (ADUS) reported GAAP revenue of $1.42B (+23.2% vs. FY2024 revenue of $1.15B , and +34.4% cumulative change since FY2023) , GAAP net income of $95.9M, operating cash flow of $111.5M, and free cash flow of $103.8M (-6.0% YoY). On the balance sheet, ADUS closed FY2025 with $1.44B in total assets against $121.0M in total debt (Altman Z-Score: 5.83, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.42B	$95.9M	$111.5M	$103.8M	$1.44B	$121.0M
FY2024 (FY)	2024-12-31	$1.15B	$73.6M	$116.4M	$110.4M	$1.41B	$218.4M
FY2023 (FY)	2023-12-31	$1.06B	$62.5M	$112.2M	$112.2M	—	—

3. ADUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Addus HomeCare Corporation (NASDAQ: ADUS) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $124.34 (+1.77% 1D, market cap $2.32B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, ADUS ranks #101 in composite RQD confidence.

How does ADUS compare to WGS and PRVA in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), ADUS carries a Roarable C+ (69/100 RQD), trailing P/E of 24.2x, gross margin of 32.5%, and ROIC of 9.1%. By comparison, WGS (GeneDx Holdings Corp. (Class A)) holds a D+ grade (58/100 RQD, P/E N/A, ROIC -4.1%, cap $2.12B) and PRVA (Privia Health Group Inc.) posts a D+ grade (57/100 RQD, P/E 122.6x, ROIC 10.5%, cap $2.81B). Among the 5-stock peer group, ADUS leads on earnings multiple (24.2x) while AVAH leads on capital efficiency (15.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ADUS?

Per ADUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468328), Addus HomeCare Corporation generated $1.42B in revenue (+23.2% YoY), $95.9M in net income, and $103.8M in free cash flow against $1.44B in total assets and $121.0M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ADUS trading relative to its 50-day, 200-day, and 52-week technical levels?

ADUS last traded at $124.34 (+1.77% on volume of 331,621 shares), positioning the stock +6.27% above its 50-day simple moving average ($117.00) and +16.92% above its 200-day simple moving average ($106.35). Across its 52-week range of $87.95 to $126.62, ADUS sits at the 94.1% percentile with a 14-day RSI of 73.1 (OVERBOUGHT (>70)) and an implied next-earnings move of ±5.0% ($118.12 to $130.56).